Table 2.
Changes in patients’ characteristics after FCM administration
| Variable | First assessment | Second assessment | P‐value |
|---|---|---|---|
| Laboratory data | |||
| NT‐proBNP, pg/mL | 3868 (1680‐4841) | 3120.5 (1430‐5788) | 0.674 |
| eGFR, mg/dL/1.73 m2 | 38 (26‐47) | 44 (29‐51) | 0.123 |
| Hemoglobin, g/dLa | 12.2 ± 1.7 | 12.8 ± 1.9 | 0.088 |
| Ferritin, mg/dL | 126 (32‐210) | 620 (535‐814) | 0.012 |
| Transferrin saturation, % | 17.65 (15.3‐19.8) | 29.6 (28.05‐31.35) | 0.012 |
| Vital signs | |||
| SBP, mmHga | 122 ± 14 | 130 ± 24 | 0.134 |
| DBP, mmHga | 61 ± 10 | 69 ± 18 | 0.136 |
| Heart rate, bpm | 72 (65.5‐87) | 68.5 (60‐87) | 0.205 |
| Functional capacity | |||
| NYHA class≥III | 5 (63%) | 1 (13%) | 0.039 |
| 6MWT | 198 (160‐236) | 276 (169‐342) | 0.011 |
| Quality of life | |||
| MLHFQ | 55 (18‐68) | 27 (15‐48) | 0.293 |
FCM: ferric carboximaltose; NT‐proBNP: amino‐terminal pro‐brain natriuretic peptide; eGFR: estimated glomerular filtration rate; SBP: systolic blood pressure; DBP: diastolic blood pressure; 6MWT; 6‐minute walk test; MLHFQ: Minnesota Living with Heart Failure questionnaire
Values for continuous variables are expressed as median (interquartile range) unless otherwise specified.
a
Variable expressed as mean ± standard deviation.